A selection of our portfolio

Developing transformative medicines for patients living with debilitating and life-threatening neurodegenerative disorders

Developing novel immunotherapeutics known as Alphamers®, which redirect a patient’s existing antibodies to kill cancer cells and boost immune surveillance

Developing activators of free fatty acid receptors to treat metabolic diseases, including type 2 diabetes and non-alcoholic steatohepatitis (NASH)

Developing personalised digital healthcare solutions to improve outcomes for patients and clinicians

Their next-generation integrated physiological and digital biomarker platform can monitor diseases of the central nervous system at home – providing feedback on disease progression and response to treatment

Developing novel antibodies to G-protein coupled receptor (GPCR) targets to treat inflammatory diseases (chronic kidney disease and myeloid driven inflammatory disease) using their proprietary HEPTAD discovery technology

Developing novel therapies for inflammation and autoimmune disease

Developing ETX-810 to treat chronic pain, and ETX-155, to treat major depressive disorder, perimenopausal depression and focal onset seizures. LifeArc invested alongside RA Capital, Intermediate Capital Group, Access Biotechnology, Samlyn Capital and Acorn Bioventures in a $60 million Series B financing in May 2021.

Developing novel, differentiated gene therapies for eye conditions, including diabetic macular oedema, age-related macular degeneration (AMD) and intra-ocular hypertension

Discovering and developing small molecules to promote remyelination to treat multiple sclerosis